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Abstrat
This artile fouses on parameter estimation of multi-levels nonlinear mixed eets mod-
els (MNLMEMs). These models are used to analyze data presenting multiple hierarhial
levels of grouping (luster data, linial trials with several observation periods,...). The
variability of the individual parameters of the regression funtion is thus deomposed as
a between-subjet variability and higher levels of variability (for example within-subjet
variability). We propose maximum likelihood estimates of parameters of those MNLMEMs
with two levels of random eets, using an extension of the SAEM-MCMC algorithm. The
extended SAEM algorithm is split into an expliit diret EM algorithm and a stohasti
EM part. Compared to the original algorithm, additional suient statistis have to be
approximated by relying on the onditional distribution of the seond level of random ef-
fets. This estimation method is evaluated on pharmaokineti ross-over simulated trials,
mimiking theophyllin onentration data. Results obtained on those datasets with either
the SAEM algorithm or the FOCE algorithm (implemented in the nlme funtion of R soft-
ware) are ompared: biases and RMSEs of almost all the SAEM estimates are smaller than
the FOCE ones. Finally, we apply the extended SAEM algorithm to analyze the pharma-
okineti interation of tenofovir on atazanavir, a novel protease inhibitor, from the ANRS
107-Puzzle 2 study. A signiant derease of the area under the urve of atazanavir is found
in patients reeiving both treatments.
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1 Introdution
The use of non-linear mixed eets models (NLMEMs) inreases in several elds suh as agron-
omy, forestry, linial trials, population pharmaokinetis (PK) and pharmaodynamis or viral
dynamis to model longitudinal data. In some settings, data an present multiple hierarhial
levels of grouping, leading to multiple nested levels of variability. For instane, we may study
patients that are grouped in medial servies that are themselves grouped into hospitals. In this
artile, we all multilevel non-linear mixed eets models (MNLMEMs) the models that desribe
suh data. MNLMEMs represent a natural extension of models with single variability level, and
they have reently been subjet to a great deal of attention in statistial literature. In the eld
of forestry, Hall and Clutter (1) analyze longitudinal measures of yield and growth that are mea-
sured on eah tree within a plot. In the eld of agronomy, Rekaya et al. (2) onsider milk yield
data where eah ow is observed longitudinally during its rst three latations. Jarézi et al.
(3) perform geneti analyses of growth measurements in beef attle aknowledging the fat that
several ows ome from the same sire. Another example is population PK, where onentration
measurements may be taken with several patients over several distint time intervals, that are
often named periods or oasions. That grouping pattern is used for instane in PK ross-over
trials.
In NLMEMs with only one level of variability, often orresponding to between-subjet vari-
ability, the analysis results in the estimation of the xed eets parameters and of the between-
subjet variability of the parameters, also alled inter-subjet variability. When there is more
than one level of grouping, the higher levels of variability an be estimated. In the spei ase
where the seond level of grouping orresponds to multiple periods of measurement, this variabil-
ity is alled within-subjet variability (or intra-subjet variability, or inter-oasion variability),
and orresponds to the variation of the individual parameters aross the dierent study periods
or units. In the ontext of pharmaokinetis, Karlsson et al. (4) demonstrate the importane
of modeling this seond level of variability in two-levels NLMEMs. They show that negleting
it resulted in biased estimates for the xed eets.
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The parameter estimation of NLMEMs is not trivial beause the likelihood of NLMEMs
annot be expressed in a losed form due to the non-linearity of the regression funtion in the
random eets. Therefore, several estimation methods have been proposed. The First Order
Conditional Estimates (FOCE) algorithm performs a rst order linearization of the regression
funtion with respet to the random eets (5; 6). The implementation of the FOCE algorithm
in the NONMEM software and in the nlme funtion of Splus and R enables the estimation of both
between- and within-subjet variabilities. From our pratie, the main drawbak of this method
is however that it does not always onverge when one estimates simultaneously the between-
and the within-subjet variabilities on several parameters. Furthermore, this linearization-based
method annot be onsidered as fully established in theory. For instane, Vonesh (7) and Ge
et al. (8) give examples of spei designs resulting in inonsistent estimates, suh as when the
number of observations per subjet does not inrease faster than the number of subjets or when
the variability of random eets is too large.
Several estimation methods have been proposed as alternatives to linearization algorithms.
A ommon method to handle numerial integration is the adaptative Gaussian quadrature
(AGQ) method. An estimation algorithm of NLMEM parameters based on this lassial AGQ
method has been proposed by Pinheiro and Bates (9) and is implemented in the SAS proedure
NLMIXED (10). However, the AGQ method requires a suiently large number of quadrature
points implying an often slow onvergene with very high omputational time. Furthermore,
two-levels NLMEM an be implemented in the NLMIXED proedure, but to our knowledge,
the onvergene is diult to obtain in pratie (3). Improvements upon this method are thus
needed. The seond alternative to linearization is the use of the Expetation-Maximization (EM)
algorithm (11) in order to estimate models with missing or non-observed data suh as random
eets. Beause of the nonlinearity of the model, stohasti versions of the EM algorithm have
been proposed. Wei et al. (12); Walker (13) and Wu (14) propose MCEM algorithms, with a
Monte-Carlo approximation of the E-step. However the MCEM algorithm may have omputa-
tional problems (i.e slow or even non onvergene). As an alternative to address omputational
problems, a stohasti approximation version of EM (SAEM) has been proposed in (15; 16),
whih requires the simulation of only one realization of the missing data for eah iteration, sub-
stantially reduing the omputation time. Kuhn and Lavielle (16) propose to ombine the SAEM
algorithm with a Monte-Carlo Markov Chain (MCMC) proedure adapted to the NLMEMs, and
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prove that the resulting estimates are onvergent and onsistent.
To date, none of the EM-based algorithms are diretly appliable to the ase of multilevel
NLMEMs and have to be adapted. The objetive of this paper is to extend the SAEM algo-
rithm to MNLMEMs with two levels of variability: both E and M steps need to be adapted
to integrate higher levels of random eets. We also propose estimates of the likelihood and of
the Fisher information matrix. We evaluate this algorithm on a PK example, more preisely a
two-periods one-sequene ross-over trials simulated mimiking theophyllin onentration data
(9). We also apply the SAEM algorithm to the PK interation of two HIV moleules (tenofovir
and atazanavir) from a PK substudy of the ANRS 107-Puzzle 2 trial. After desribing the
model and notations (setion 2), setion 3 desribes the SAEM algorithm. Setion 4 reports
the simulation study and its results. In Setion 5, we study the PK interation of tenofovir on
atazanavir in HIV patients. Setion 6 onludes the artile with some disussion.
2 Models
Let us denote yijk the observation in unit k (k = 1, . . . ,K) for subjet i (i = 1, · · · , n) and at
time tijk (j = 1, · · · , nik). For instane, the dierent units an be the dierent periods in the
ase of PK trials, or the dierent parents in the ase of geneti analyses. We assume, as a known
fat, two nonlinear funtions f and g suh that the two-levels non-linear mixed eets model
linking observations to sampling times an be written as:
yijk = f(tijk, φik) + g(tijk, φik)εijk,
εijk ∼ N (0, σ
2),
where φik is the p-vetor of the parameters of subjet i for unit k and εijk is the measurement
error. We hypothesize that the errors εijk given φik are mutually independent. We assume that
the individual parameters φik are random vetors and that for eah unit k, φik an be broken
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into:
φik = µ+ βk + bi + cik, (1)
bi ∼ N (0,Ω),
cik ∼ N (0,Ψ),
where µ + βk is the mean value for unit k, bi is the random eet of size p of subjet i, and
cik is the random eet of size p of subjet i and unit k. To ensure the identiability of the
parameters, we assume that β1 = 0, ie µ is the mean of the rst unit and βk represents the
dierene (or eet) of the kth unit in omparison to this rst unit. The random eets (bi)
and (cik) are assumed to be mutually independent. The total variane of the parameters is
thus broken into a between-subjet variane Ω and a within-subjet variane Ψ. Finally, the
individual parameters pK-vetor φi = (φi1, . . . , φiK) of subjet i is distributed with a Gaussian
distribution with mean vetor (µ, µ+β2, . . . , µ+βK) and a pK× pK ovariane matrix Γ equal
to
Γ =

Ω+Ψ Ω . . . Ω
Ω Ω+ Ψ
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. Ω
Ω . . . Ω Ω+Ψ

.
Let θ = (µ, β,Ω,Ψ, σ2), the vetor of all the parameters of the model where β denotes the
vetor of unit eet β = (β1, . . . , βK). The aim of this paper is to propose an estimation of θ
by maximizing the likelihood of the observations y = (yijk)ijk.
Let us denote b˜i := µ+ bi. The likelihood of y an be written as:
p(y; θ) =
∫
p(y, φ, b˜; θ)d(φ, b˜)
where p(y, φ, b˜; θ) is the likelihood of the omplete data (y, φ, b˜), with φ = (φik)i=1,...,n,k=1,...,K
and b˜ = (b˜1, . . . , b˜n). Beause of the nonlinearity of the regression funtion f with respet to
the random eets φik, the likelihood has no losed form. Therefore, the maximization of the
likelihood in θ, θ ∈ Θ, is a omplex problem. We propose to use a stohasti version of the EM
algorithm, whih is presented in detail in the next setion.
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3 Estimation algorithm
3.1 The SAEM algorithm
The EM algorithm introdued by Dempster et al. (11) is a lassial approah to estimate param-
eters of models with non-observed or inomplete data. In two-levels NLMEMs, the non-observed
data are the individual parameters (φ, b˜) and the omplete data of the model is (y, φ, b˜). Let us
denote Lc(y, φ, b˜; θ) = log p(y, φ, b˜; θ) the log-likelihood of the omplete data. The priniple of
the iterative EM algorithm is to maximize the funtion Q(θ|θ′) = E(Lc(y, φ, b˜; θ)|y; θ′) where
the expetation is the onditional expetation under the posterior distribution p(φ, b˜|y; θ′), the
maximization of Q being often easier than the diret maximization of the observed data log-
likelihood. Eah iteration of the EM algorithm is omputed through two steps: the Expetation
step (E-step) and the Maximization step (M-step). At the ℓth iteration of the algorithm, the E
step is the evaluation of Q(θ | θ̂ℓ), while the M step updates θ̂ℓ by maximizing Q(θ | θ̂ℓ).
Let us show that the funtion Q an be redued in the ase of a MNLMEM. First, let us
note that as p(b˜|y, φ; θ) = p(b˜|φ; θ), by appliation of the Bayes theorem we have:
p(φ, b˜|y; θ) = p(b˜|φ; θ)p(φ|y; θ) =
n∏
i=1
p(b˜i|φi; θ)p(φi|yi; θ). (2)
Seond, through the linearity of the individual parameters model in equation (1), the poste-
rior distribution p(b˜i|φi; θ) of the ith subjet is expliit: p(b˜i|φi; θ) is a Gaussian distribution
N (m(φi, θ), V (θ)) of mean and variane equal to:
m(φi, θ) = V (θ)
(
Ψ−1
K∑
k=1
(φik − βk) + Ω
−1µ
)
, (3)
V (θ) = (Ω−1 +KΨ−1)−1.
Due to the fatorization given in equation (2), funtion Q an be rewritten as:
Q(θ|θ′) =
∫ (∫
Lc(y, φ, b˜; θ)p(b˜|φ; θ
′)db˜
)
p(φ|y; θ′)dφ.
Beause of the expliit posterior distribution of random eets b˜ given in equation (3), the
omputation of this onditional expetation an be split into two parts : the omputation of
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the integral with respet to the posterior distribution of b˜ whih has an analytial form, and
the omputation of the integral with respet to the posterior distribution of φ whih has no
analytial form. Therefore the EM algorithm is split into an expliit diret EM algorithm for
the omputation of the rst integral and the use of a stohasti version of the EM algorithm for
the omputation of the seond integral.
Let us detail the expliit omputation of the rst integral, denoted by R(y, φ, θ, θ′)
R(y, φ, θ, θ′) =
∫
Lc(y, φ, b˜; θ)p(b˜|φ; θ
′)db˜.
This integral has an analytial form. Indeed, the omplete log likelihood Lc(y, φ, b˜; θ) is equal
to
Lc(y, φ, b˜; θ) = −
1
2
K∑
k=1
n∑
i=1
nik∑
j=1
log(2πσ2g2(tijk , φik))−
1
2
K∑
k=1
n∑
i=1
nik∑
j=1
(yijk − f(tijk, φik))2
σ2g2(tijk, φik)
−
nK
2
log(2π detΨ)−
1
2
K∑
k=1
n∑
i=1
(φik − b˜i − βk)
tΨ−1(φik − b˜i − βk)
−
n
2
log(2π detΩ)−
1
2
n∑
i=1
(b˜i − µ)
tΩ−1(b˜i − µ).
As the posterior distribution p(b˜|φ; θ) is known (equation 3), R(y, φ, θ, θ′) is equal to
R(y, φ, θ, θ′) = −
1
2
∑
i,j,k
log(2πσ2g2(tijk, φik))
1
2
∑
i,j,k
(yijk − f(tijk, φik))2
σ2g2(tijk, φik)
(4)
−
nK
2
log(2π detΨ)−
nK
2
Ψ−1/2V (θ′)Ψ−1/2 −
1
2
∑
i,k
(φik −m(φi, θ
′)− βk)
tΨ−1(φik −m(φi, θ
′)− βk)
−
n
2
log(2π detΩ)−
n
2
Ω−1/2V (θ′)Ω−1/2 −
1
2
n∑
i=1
(m(φi, θ
′)− µ)tΩ−1(m(φi, θ
′)− µ).
Therefore Q is redued to the omputation of the seond integral under the posterior distri-
bution p(φ|y; θ) as follows:
Q(θ|θ′) =
∫
R(y, φ, θ, θ′)p(φ|y; θ′)dφ. (5)
Given the non-linearity of funtion f with respet to φ, the posterior distribution p(φ|y; θ′) has
no losed form and the funtion Q dened by (5) is intratable. Thus we propose to use the
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stohasti version SAEM of the EM algorithm proposed by Delyon et al. (15) whih evaluates
the integral Q by a stohasti approximation proedure.
Let us detail this SAEM algorithm in the ase of two-levels NLMEMs. Let us note that the
quantity R(y, φ, θ, θ′) belongs to the regular urved exponential family, i.e, it an be written as
R(y, φ, θ, θ′) = −Λ(θ) + 〈S(y, φ, θ′),Φ(θ)〉, (6)
where 〈., .〉 is the salar produt, Λ and Φ are two funtions twie ontinuously dierentiable
on Θ and S(y, φ, θ′) is known as the minimal suient statistis of the omplete model. Those
statistis are detailed later. In this ase, the Q funtion is redued to
Q(θ|θ′) = −Λ(θ) + 〈
(∫
S(y, φ, θ′)p(φ|y; θ′)dφ
)
, Φ(θ) 〉,
In this ase, at the ℓth iteration, the SAEM algorithm proeeds as follows:
• Simulation step: simulation of the missing data (φ
(ℓ)
i )i under the onditional distribution
p(φ|y; θ̂ℓ)
• Stohasti approximation step: omputation of a stohasti approximation sℓ+1 ofE
[
S(y, φ, θ̂ℓ)|y; θ̂ℓ
]
=∫
S(y, φ, θ̂ℓ)p(φ|y; θ̂ℓ)dφ, using (γℓ)ℓ≥0, a sequene of positive numbers dereasing to 0:
sℓ+1 = sℓ + γℓ(S(y, φ
(ℓ), θ̂ℓ)− sℓ).
• Maximization step: update of the estimate θ̂ℓ+1:
θ̂ℓ+1 = argmax
θ∈Θ
(−Λ(θ)) + 〈sℓ+1,Φ(θ))〉) .
The suient statistis of the omplete model (4) evaluated during the SA step of the SAEM
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algorithm are as follows:
s1,i,ℓ+1 = s1,i,ℓ + γℓ
(
K∑
k=1
φ
(ℓ)
ik − s1,i,ℓ
)
, i = 1, . . . , N,
s2,k,ℓ+1 = s2,k,ℓ + γℓ
(
n∑
i=1
φ
(ℓ)
ik − s2,k,ℓ
)
, k = 1, . . . ,K,
s3,ℓ+1 = s3,ℓ + γℓ
(
n∑
i=1
m(φ
(ℓ)
i , θ̂ℓ)
tm(φ
(ℓ)
i , θ̂ℓ)− s3,ℓ
)
,
s4,ℓ+1 = s4,ℓ + γℓ
(
K∑
k=1
n∑
i=1
(
φ
(ℓ)
ik −m(φ
(ℓ)
i , θ̂ℓ)
)t (
φ
(ℓ)
ik −m(φ
(ℓ)
i , θ̂ℓ)
)
− s4,ℓ
)
,
s5,ℓ+1 = s5,ℓ + γℓ
∑
i,j,k
(
yijk − f(tijk, φ
(ℓ)
ik )
g(tijk, φ
(ℓ)
ik )
)2
− s5,ℓ
 ,
The expression of the M step is obtained by derivation of equation (4). The parameter estimates
are as follows:
µ̂ℓ+1 = V (θ̂ℓ)Ψ̂
−1
ℓ
(
1
n
n∑
i=1
s1,i,ℓ+1 −
K∑
k=1
β̂k,ℓ
)
+ V (θ̂ℓ)Ω̂
−1
ℓ µ̂ℓ,
β̂k,ℓ+1 =
s2,k,ℓ+1
n
− µ̂ℓ+1, for k = 2, . . . ,K,
Ω̂ℓ+1 = V (θ̂ℓ) +
s3,ℓ+1
n
− (µ̂ℓ+1)
tµ̂ℓ+1,
Ψ̂ℓ+1 = V (θ̂ℓ) +
s4,ℓ+1
nK
−
1
K
K∑
k=1
(β̂k,ℓ+1)
tβ̂k,ℓ+1,
σ̂2ℓ+1 =
s5,ℓ+1∑n
i=1
∑K
k=1 nik
.
Comparing with the lassi SAEM algorithm for single-level NLMEMs, the extension of
SAEM to the two-levels NLMEMs is nally split into an expliit EM algorithm and a stohasti
EM part. Furthermore, it requires the omputation of two intermediate quantities (the ondi-
tional expetationsm(φi, θ) and variane V (θ) of the between-subjet random eets parameters
bi) as well as two additional suient statistis (S3 and S4), funtions of m(φi, θ). The M-step
diers from the one of the lassi SAEM for single-level NLMEMs, espeially for the estimation
of the variane matrix Ω and Ψ whih uses the additional quantity V (θ).
As proved by (15; 17), the onvergene of the SAEM algorithm is ensured under the following
assumption:
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Assumption (A1):
1. Funtions Λ and Φ are twie ontinuously dierentiable on Θ.
2. The log-likelihood log p(y; θ) is d times dierentiable on Θ, where d is the dimension of
S(y, φ, θ′).
3. Funtion s¯ dened as
s¯(θ, θ′) =
∫
S(y, φ, θ′)p(φ|y; θ)dφ
is ontinuously dierentiable on Θ with respet to its rst variable.
4. For all ℓ in N, γℓ ∈ [0, 1],
∑∞
ℓ=1 γℓ = ∞ and
∑∞
ℓ=1 γ
2
ℓ <∞.
For a onvenient step sizes sequene γℓ, the assumption (A1) is trivially heked in our model.
A hoie of step sizes sequene γℓ is presented in Setion 4.
However, the simulation step of the SAEM algorithm, whih performs the simulation of the
non-observed vetor φ under the posterior distribution p(φ|y; θ) annot be diretly performed
beause the posterior distribution is only known up to a onstant. In this ase, Kuhn and Lavielle
(16) propose to ombine the SAEM algorithm with a Markov Chain Monte Carlo (MCMC)
proedure for the simulation step. This version of the SAEM-MCMC algorithm an be used for
the estimation of MNLMEMs. The MCMC proedure used in this ase is detailed in setion 3.2.
As proved by (17), the onvergene of the SAEM-MCMC algorithm is ensured under assumption
(A1) and the following additional assumption:
Assumption (A2):
For any θ in Θ, we assume that the onditional distribution p(.|y; θ) is the unique limiting
distribution of a transistion probability Πθ, that has the following properties:
1. For any ompat subset V of Θ, there exists a real onstant L suh that for any (θ, θ′) in
V 2
sup
{φ,φ′}∈E
|Πθ (φ
′|φ)−Πθ′ (φ
′|φ)| ≤ L‖θ− θ′‖.
2. The transition probability Πθ supplies an uniformly ergodi hain whose invariant proba-
bility is the onditional distribution p(φ|y; θ), i.e.
∃Kθ ∈ R
+, ∃ρθ ∈]0, 1[ | ∀ℓ ∈ N ‖Π
ℓ
θ(·|φ) − p(·, ·|y; θ)‖TV ≤ Cθρ
ℓ
θ,
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where ‖ · ‖TV is the total variation norm. Furthermore,
C = sup
θ∈Θ
Cθ <∞ and ρ = sup
θ∈Θ
ρθ < 1.
3. Funtion S is bound on E .
At iteration ℓ, the S-step of the SAEM-MCMC algorithm onsists thus in simulating φ(ℓ) with
the transistion probability Πθˆℓ
(
φ(ℓ−1)|dφ(ℓ)
)
.
The assumption (A2.2) is the most deliate to hek, and it depends on the hoie of the
MCMC algorithm. This is detailed in the next subsetion after presenting the MCMC proedure.
In pratie, the SAEM algorithm being a stohasti algorithm, there exists no deterministi
onvergene riterion whih ould be used to stop the iterations of the algorithm as soon as the
onvergene is reahed. Therefore, we reommend to implement the SAEM algorithm with a
suiently large number of iterations and to graphially hek the onvergene by plotting the
values of the SAEM estimates obtained along iterations versus the iterations. Suh a gure is
desribed in Setion 4.
3.2 MCMC algorithm for the simulation step
Let us detail the simulation step of the SAEM-MCMC algorithm, whih performs the simula-
tion of the missing data φ through a Markov hain whih has p(φ|y; θ) as unique stationary
distribution. For subjet i, by Bayes formula, this onditional distribution is proportional to
p(φi|yi; θ) ∝
K∏
k=1
p(yik|φik; θ)p(φi; θ).
We propose to use a Metropolis-Hastings (M-H) algorithm to simulate this Markov hain.
Let us reall the priniple of this algorithm. At iteration r of the M-H algorithm, given the
urrent value φ
(r)
i of the Markov Chain, the M-H algorithm proeeds as follows:
1. Simulate φci with a proposal distribution q(·, φ
(r)
i )
2. Compute the aeptane probability
α(φci , φ
(r)
i ) =
∏K
k=1 p(yik|φ
c
ik; θ)p(φ
c
i ; θ)∏K
k=1 p(yik|φ
(r)
ik ; θ)p(φ
(r)
i ; θ)
q(φci , φ
(r)
i )
q(φ
(r)
i , φ
c
i )
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3. Simulate u with a uniform distribution U [0, 1]
4. Update the Markov hain with
φ
(r+1)
i =
 φ
c
i if u ≤ α(φ
c
i , φ
(r)
i )
φ
(r)
i else
The onvergene of the M-H algorithm strongly depends on the hoie of the proposal distribu-
tion q. The onvergene is ensured for some proposal distributions suh as independent (q(·, φ
(r)
i )
independent of φ
(r)
i ) or symmetrial (q(·, φ
(r)
i ) = q(φ
(r)
i , ·)) proposals (18). These proposals are
detailed below. Given the dimension of φ, we also onsider a Metropolis-Hastings-Within-Gibbs
algorithm, ombining both Gibbs algorithm and M-H proedure. The advantage of the Gibbs
algorithm is to redue the multi-dimensional simulation problem to the suessive simulations of
one-dimension vetors. Finally, at iteration ℓ of the SAEM algorithm, given the urrent estimate
θ̂ℓ, we ombine the three following proposal transitions:
1. the prior distribution of φi, that is the Gaussian distribution N (µ̂ℓ+ β̂ℓ, Γ̂ℓ), orresponding
to an independent M-H algorithm,
2. the multidimensional random walks N (φ
(ℓ−1)
i , ρΓ̂ℓ) (symmetri proposal), where ρ is a
saling value hosen to ensure a satisfatory aeptation rate, namely around 30% as
proposed in (19),
3. a suession of Kp unidimensional Gaussian random walks (symmetri proposal), i.e eah
omponent of φi is suessively updated, leading to a Metropolis-Hastings-Within-Gibbs
algorithm,
where Γ̂ℓ is equal to
Γ̂ℓ =

Ω̂ℓ + Ψ̂ℓ Ω̂ℓ . . . Ω̂ℓ
Ω̂ℓ Ω̂ℓ + Ψ̂ℓ
.
.
.
.
.
.
.
.
.
.
.
.
.
.
. Ω̂ℓ
Ω̂ℓ . . . Ω̂ℓ Ω̂ℓ + Ψ̂ℓ

.
Given the proposal distributions, as previously detailed, and using the theoretial onvergene
results proposed in (18), this hybrid Gibbs algorithm onverges and generates an uniformly
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ergodi hain with p(φ|y; θ) as the stationary distribution. Consequently, by applying the on-
vergene theorem of Kuhn and Lavielle (16) and under assumptions (A1) and (A2), we prove that
the estimate sequene (θ̂ℓ)ℓ≥0 produed by the extended SAEM algorithm onverges towards a
(loal) maximum of the likelihood p(y; θ).
In pratie, the onvergene of the MCMC algorithm is diult to verify. As in Bayesian
inferene, the only onvergene riteria existing for MCMC proedure are graphial riteria. We
have to hek if the estimate sequene explores a suieny large domain of the Markov hain.
A onvergene gure is presented and ommented in setion 4.
3.3 Estimation of the Fisher information matrix and the likelihood
To perform statistial tests suh asWald test or likelihood ratio test, we propose estimators of the
Fisher information matrix and the likelihood, respetively. As the Fisher information matrix has
no losed form in MNLMEMs, we propose to approximate it by the Fisher information matrix
of the multi-level linear mixed model dedued from the MNLMEM after linearization of the
funtion f around the onditional expetation of the individual parameters (E(φi|y; θˆ), 1 ≤ i ≤
n). The omputation of this linearized Fisher information matrix is diret and does not need
any approximation.
The estimation of the likelihood of the MNLEM is based on an Importane Sampling pro-
edure, as proposed by Samson et al. (20) for NLMEMs. The Importane Sampling proedure
has been introdued to approximate the integral of the likelihood with a smaller variane than
with other Monte Carlo methods. In this ase, an estimate of the ontribution p(yi; θ) of the
individual i to the likelihood is
p̂(yi; θ) =
1
T
T∑
t=1
p(yi, φ
(t)
i ; θ)
qi(φ
(t)
i )
where (φ
(t)
i )t=1,...,T are simulated using the individual instrumental distribution qi. As an in-
dividual instrumental distribution qi, we propose a Gaussian approximation of the individual
onditional posterior distribution p(φi|yi; θ).
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4 Simulation study: a PK example
4.1 Simulation settings
The objetive of this simulation study is to illustrate the main statistial properties of the
extended SAEM algorithm (bias, root mean square errors, group omparison tests) and to
ompare them to the FOCE algorithm. We do not use the AGQ algorithm, sine proedure
NLMIXED does not sueed, in pratie, in estimating suh omplex variane models.
We use the PK data of orally administered theophyllin to dene the population model for the
simulation study. These data are lassial ones in population pharmaokinetis, often used for
software evaluation (21). We assume that onentrations an be desribed by a one-ompartment
model with rst order absorption and rst order elimination:
f(t, φ) =
DKa
V Ka − Cl
(
e−
Cl
V
t − e−Kat
)
whereD is the dose, V is the volume of distribution, Ka is the absorption rate onstant and Cl is
the learane of the drug elimination. These parameters are positive and distributed aording to
a log-normal distribution. Thus, φ has the following omponents: φ = (logV, logKa, logAUC),
with AUC = D/Cl. We assume idential sampling times for all subjets: for all i in 1, . . . , n,
k = 1, 2, tijk = tj for j = 1, . . . , J . Additive Gaussian random eets are assumed for eah
parameter with a diagonal ovariane matrix Ω and a a diagonal ovariane matrix Ψ. Let
ω2 = (ω2V , ω
2
Ka
, ω2AUC) and ψ
2 = (ψ2V , ψ
2
Ka
, ψ2AUC) denote the vetor of the varianes of the
random eets. A ombined error model is assumed by setting g(t, φ) = 1 + f(t, φ).
We set the dose for all subjets to the value of 4 mg. For all the parameters, the values are
those proposed by Panhard and Mentré (22): logV = −0.73, logKa = 0.39 and logAUC = 4.61,
ω2V = 0.01, ω
2
Ka
= 0.04, ω2AUC = 0.04, ψ
2
V = 0.0025, ψ
2
Ka
= 0.01, ψ2AUC = 0.01 and σ
2 = 0.01.
We generate n = 24 and n = 40 total numbers of subjets with J = 10 blood samples per
subjet, taken at 15 minutes, 30 minutes, 1, 2, 3.5, 5, 7, 9, 12 and 24 hours after dosing. The
individual data of one simulated trial are displayed in Figure 1.
[Figure 1 about here.℄
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4.2 Evaluation of estimates
Our aim is to evaluate and ompare the estimates produed by the extended SAEM algorithm
with those produed by the nlme funtion of the R software. We t the simulation model and
ompute the relative bias and relative root mean square error (RMSEs) for eah omponent of
θ from 1000 repliations of the two trials desribed below (n = 24 and n = 40 total number of
subjets).
The simulation model inludes a treatment eet on all omponents of θ. We test the null
hypothesis {βlogAUC = 0} using the Wald test. We also t the model where the treatment eet
on logAUC is not estimated, and test the same null hypothesis using the Likelihood Ratio Test
(LRT).
The SAEM algorithm is implemented with 500 iterations. During the rst 200 iterations, a
onstant step size γℓ = 1 is hosen, in order to let the Markov hain explore the parameters do-
main. Then during the last 300 iterations, the stohasti approximation sheme is implemented
with a step size equal to γℓ =
1
ℓ−200 at iteration ℓ. This hoie of step size sequene veries
onvergene assumption (A1.1). The evolution of eah SAEM parameter estimates is plotted
against iterations (logarithmi sale) on Figure 2. During the rst iterations of the SAEM
algorithm, the estimate sequenes explore randomly some neighborhoods of the initial values,
through the Markov hain simulation. In partiular, these behaviors are learly visible for the
xed eet parameters (µ and β). After 200 iterations, the estimates onverge then rapidly to a
neighborhood of the maximum likelihood, due to the stohasti approximation sheme. In this
example, the iteration number has been hosen suh that the onvergene is learly attained
before the last iteration.
[Figure 2 about here.℄
The relative bias and RMSEs obtained on the 1000 datasets with n = 24 and n = 40 subjets
are presented in Table 1.
[Table 1 about here.℄
The bias and the RMSEs of the xed eets (µ) are small with the SAEM algorithm and are
almost half of those obtained with nlme (espeially the RMSEs). The bias and RMSEs of the
unit eet (β) are small and on the same order with both methods. For the between-subjet
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variability parameters (Ω), the bias are redued with SAEM, while the RMSEs are of the same
order with both methods. For the within-subjet variability parameters (Ψ), the bias and the
RMSEs are satisfatory, and on the same order with both methods. The bias and RMSE for σ2
are small and satisfatory for both methods.
The type I error of the Wald test and of the LRT are evaluated on the same 1000 datasets.
For n = 24, the type I errors are 6.0% and 6.5% for SAEM and nlme, respetively, for the Wald
test, and 4.6% and 5.6% for SAEM and nlme, respetively, for the LRT. For n = 40, the type
I error are 5.6% and 5.4% for SAEM and nlme, respetively, for the Wald test, and 5.8% and
5.2% for SAEM and nlme, respetively, for the LRT.
5 Appliation to the population pharmaokinetis of atazanavir
with tenofovir
5.1 Study population: ANRS 107 - Puzzle 2 study
The Puzzle 2 - ANRS 107 trial was a randomized open-label, multiple-dose study supported
by the Frenh Agene Nationale de Reherhe sur le Sida (ANRS) with HIV-infeted patients
in treatment failure with their antiretroviral therapy. Patients were randomized to reeive for
the rst two weeks either their unhanged treatment with PIs and nuleoside reverse transrip-
tase inhibitors (NRTIs) (group 1) or unhanged treatment with NRTIs in ombination with
atazanavir (300 mg QD) plus ritonavir (100 mg QD) as a substitute for the failing PI therapy
(group 2). From week 3 (day 15) to week 26, patients from either group swithed to atazanavir
(300 mg QD) plus ritonavir (100 mg QD) plus tenofovir DF at 300 mg QD and NRTIs seleted
aording to the baseline reverse transriptase genotype of the HIV isolated in eah patient.
In this paper, we analyze onentration data obtained from 10 patients from group 2 who
were inluded and measured at 1, 2, 3, 5, 8, and 24 h after administering drug during eah
treatment period. Those exat dosing intervals were reorded. The objetive of the substudy
was to measure the pharmaokineti parameters of atazanavir (administered with ritonavir)
either before (day 14 [week 2℄) or after (day 42 [week 6℄) initiation of tenofovir DF in HIV-
infeted patients in order to detet pharmaokineti interations of tenofovir on atazanavir.
Data of this substudy were analyzed using a nonlinear mixed eet model by Panhard et al (23)
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and a signiant eet of the o-administration of tenofovir on the pharmaokineti parameters
of atazanavir was found using the nlme funtion of the Splus software.
The aim of the present analysis is to evaluate the eet of tenofovir on the PK parameters
of atazanavir using the SAEM algorithm and the Wald test desribed in setion 4.
We use the one-ompartment model with zero-order absorption proposed by Panhard et al.
(23) to desribe atazanavir onentrations:
f(t, φ) =
FD
TaCl
(
(1 − e−
Cl
V
t)1t<Ta +
e−
Cl
V
τ1t<Ta (1 − e−
Cl
V
Ta)e−
Cl
V
(t−Ta)
(1− e−
Cl
V
τ )
)
with F the bioavailability, V the volume of distribution of atazanavir, (Ta) the absorption
duration, Cl the elimination learane and τ the dosing interval (24 hours until the PK visit).
The vetor of the logarithm of the identiable parameters is φ = (log(V/F ), log(Ta), log(AUC)).
Data of both treatment periods are simultaneously analyzed using a NLMEM with two levels
of variability (the between-patient and within-patient variabilities) on eah PK parameter. A
treatment eet is also estimated for eah PK parameter, and a homosedasti error model is
used.
5.2 Results
Conentrations versus time are displayed in Figure 3. The SAEM algorithm sueeds in the
estimation of all the parameters. The resulting parameters estimates are displayed in table
2. The SAEM algorithm estimates the AUC between-patient variability and the V/F and Ta
within-patient variabilities to 0.48, 0.69 and 0.19, respetively. The three other varianes are
estimated to 0.
[Table 2 about here.℄
A signiant eet of o-mediation with tenofovir is found on log(AUC) (p=0.00015) with the
Wald test based on the SAEM algorithm.
The individual predition urves for the two periods are overlaid on the onentration data on
Figure 3 for 10 patients. The goodness-of-t plots (population and individual predited onen-
trations versus observed onentrations; standardized residuals versus predited onentrations
and versus time) are judged satisfatory, and are displayed in Figure 4.
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[Figure 3 about here.℄
[Figure 4 about here.℄
6 Disussion
The main original element of this study is the development of the SAEM algorithm for two-
levels non-linear mixed eets models. We extend the SAEM algorithm developed by Kuhn and
Lavielle (16), whih was not yet adapted to the ase of MNLMEMs with two levels of random
eets. This algorithm will be implemented in the 3.1 version of the monolix software, freely
available on the following website: http://monolix.org. The two levels of random eets are the
between-subjet variane and the within-subjet (or between-unit) variane, with N subjets
and K units, with no restrition on N or K. We show that the SAEM algorithm is split into two
parts: an expliit EM algorithm and a stohasti EM part. The integration of the term p(b|φ; θ)
in the likelihood results in the derivation of two additional suient statistis ompared to the
original algorithm. Furthermore it uses two intermediate quantities, the onditional expetations
and variane of the between-subjet random eets parameters b. The addition of higher levels
of variability would therefore require other extensions of the algorithm.
The onvergene of the algorithm is monitored from a graphial riterion, as shown in Fig1.
An automati implementation of that stopping riterion to optimize both the number of itera-
tions and the stohasti approximation step should be onsidered in future work and extension
of the Monolix software.
The simulation study illustrates the auray of our approah. We show that the bias and
RMSEs obtained by the extended SAEM algorithm are satisfatory for all parameters. The
bias are redued ompared to those obtained with the FOCE algorithm implemented in the
nlme funtion of the R software. The bias are espeially divided by two for the xed eets
parameters with SAEM. Furthermore, whereas the nlme implementation of the FOCE algorithm
does not always onverge with both between- and within-patient variability on all parameters,
the extended SAEM algorithm does. We develop the tests for a dierene between the units,
and we obtain type I errors lose to the expeted 5% for the Wald test and the LRT.
The analysis of the pharmaokinetis of atazanavir with tenofovir in the Puzzle 2 - ANRS
107 trial also demonstrates the ability of the extended SAEM algorithm to detet treatment
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interation on a real data set. When testing for an interation of tenofovir on the PK of
atazanavir, the impat of tenofovir on the absorption of atazanavir is onrmed; more preisely,
a derease of the AUC of atazanavir as shown by Panhard et al. (23) is found.
We ompare the extension of SAEM to the FOCE algorithm, that is the most popular method
in population pharmaokinetis, whih is one of the largest appliation elds of NLMEM. We try
to use the NLMIXED proedure of SAS implementing Gaussian quadrature. However, proedure
NLMIXED does not sueed, in pratie, in estimating suh omplex variane models, on our
simulated data, neither on the atazanavir dataset. The next step is a omparison with a Bayesian
estimation of the parameters using Winbugs, whih is beyond the sope of this paper.
The next ambitious development would be an extension of the algorithm to the ase of
MNLMEMs with more than two levels of random eets, in order to analyze, for instane,
geneti data where more than one generation of parents are taken into aount. However, it
would be diult to develop a general estimation method sine it strongly depends on the
relation (linear or not) of the dierent levels of random eets.
To onlude, the extended SAEM algorithm ombines the statistial properties of an exat
method together with a high omputational eieny. We thus reommend the use of this
method in MNLMEMs.
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A Index of notations
Model notations
i (i = 1, · · · , n): index of subjet
j (j = 1, · · · , nik): index of measurement of subjet i for unit k
k (k = 1, . . . ,K): index of unit
tijk: measurement time in unit k for subjet i and measurement j
yijk: observation in unit k for subjet i at timetijk
y = (yijk)ijk : vetor of the observations in the K units for all the n subjet
f and g: non-linear funtions linking observations to sampling times
φik: p-vetor of the parameters of subjet i for unit k
φi = (φi1, . . . , φiK): pK-vetor of individual parameter of subjet i
φ = (φik)i=1,...,n,k=1,...,K
µ: p-vetor of the mean of the individual parameters for k = 1
βk: eet of the kth unit in omparison to this rst unit
β = (β1, . . . , βK): vetor of the unit eets
bi: random eet of size p of subjet i
b˜i := µ+ bi b˜ = (b˜1, . . . , b˜n) cik: random eet of size p of subjet i and unit k
εijk: measurement error
Ω: p× p between-subjet ovariane matrix
Ψ: p× p within-subjet ovariane matrix
Γ: pK × pK ovariane matrix of the individual parameters φi (i = 1, · · · , n)
σ2: variane of the measurement error
θ = (µ, β,Ω,Ψ, σ2): vetor of all the parameters
Algorithm notations
p(y, φ, b˜; θ): likelihood of the omplete data
Lc(y, φ, b˜; θ): log-likelihood of the omplete data
p(φ, b˜|y; θ′): posterior distribution of (φ, b˜) given (y; θ′)
p(φ|y; θ′): posterior distribution of φ given (y; θ′)
p(b˜|φ; θ): posterior distribution of b˜ given (φ; θ)
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m(φ, θ): mean of p(b˜|φ; θ)
V (θ): variane of p(b˜|φ; θ)
Q(θ|θ′) := E(Lc(y, φ, b˜; θ)|y; θ′))
R(y, φ, θ, θ′) :=
∫
Lc(y, φ, b˜; θ)p(b˜|φ; θ′)db˜
Λ(θ, θ′) and Φ(θ, θ′): funtions of Θ×Θ
ℓ: iteration number of the SAEM algorithm
φ
(ℓ)
i : missing data simulated at iteration ℓ
S(y, φ): minimal suient statistis of the omplete model of dimension d
sℓ+1: stohasti approximation of E
[
S(y, φ)|θ̂ℓ
]
(γℓ)ℓ≥0: step sizes sequene
Πθ: transition probability
q(φci , φ
(ℓ)
i ): proposal distribution of the Metropolis-Hastings (M-H) algorithm
φci : andidate simulated using q(φ
c
i , φ
(ℓ)
i )
α(φci , φ
(ℓ)
i ): aeptane probability of the M-H algorithm
u: salar sample generated with a uniform distribution U [0, 1]
Cθ and ρθ: onstants involved in the proof of uniform ergodiity of the Markov Chain
qi: instrumental distribution used for the estimation of p(yi; θ) by Importane Sampling
T : number of simulated set of parameters in Importane Sampling
PK example notations
D: drug dose
V : volume of distribution of the drug (in liters)
Ka: absorption rate onstant (in hours
−1
)
Ta: absorption duration (in hours)
Cl: learane of elimination (in liters.hours−1)
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Figure 1: Simulated theophyllin onentration data for 24 subjets during the rst period (plain
line) and during the seond period (dotted line)
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Figure 2: Evolution of the estimates, funtion of the iteration of SAEM algorithm (with a
logarithm sale for the absis axis).
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Figure 3: Individual onentrations and individual predited urves for the pharmaokinetis of
atazanavir in 10 subjets: x and ∗, observations with and without tenofovir, respetively; dotted
and plain line, individual preditions of the atazanavir pharmaokinetis with and without
tenofovir, respetively.
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Figure 4: Goodness-of-t plots for atazanavir nal population PK model: population (a) and
individual (b) predited onentrations (in ng/mL) versus observed onentrations (in ng/mL),
standardized residuals versus predited onentrations (in ng/mL) () and versus time (in hours)
(d).
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Table 1: Relative biases (%) and relative root mean square errors (RMSE) (%) of the esti-
mated parameters evaluated by the extended SAEM algorithm and the FOCE algorithm (nlme
funtion) from 1000 simulated trials.
n=24 subjets n=40 subjets
Bias RMSE Bias RMSE
SAEM nlme SAEM nlme SAEM nlme SAEM nlme
V 0.01 0.53 3.9 6.4 -0.06 0.54 2.91 5.00
ka 0.48 -1.48 14.4 24.4 0.02 -3.07 10.79 18.4
AUC -0.08 -0.20 1.0 1.5 -0.11 -0.24 0.79 1.13
βV -0.00 -0.01 3.6 3.6 -0.05 -0.06 2.83 2.80
βka -0.73 -0.76 14.2 18.8 0.24 0.27 10.73 10.60
βAUC 0.02 -0.02 0.7 1.1 0.00 1.14 0.57 1.14
ω2V -5.13 -5.92 38.7 38.4 -3.45 -4.28 30.30 30.37
ω2ka -3.99 -7.07 42.4 41.5 -3.23 -4.63 33.49 33.32
ω2AUC -4.88 -7.29 34.5 34.2 -1.51 -3.80 27.41 27.02
ψ2V -8.67 -7.29 69.4 68.5 -5.93 -4.91 58.78 57.81
ψ2ka -10.94 -9.09 73.5 72.0 -7.06 -5.17 62.00 60.60
ψ2AUC -5.37 -5.37 43.6 42.6 -4.92 -5.79 33.31 32.47
σ2 -0.33 -0.10 7.7 7.7 0.28 0.67 6.03 6.09
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Table 2: Pharmaokineti parameters of atazanavir (estimate and SE (%)) estimated with the
SAEM
Parameters Estimate SE (%)
log(V/F ) (L) 4.01 5.79
log(Ta) (h) 1.36 6.72
log(AUC) (ng.mL−1.h) 10.67 1.61
βV/F 0.12 267.43
βTa 0.33 45.03
βAUC -0.38 25.31
ωV/F 0 -
ωTa 0 -
ωAUC 0.48 25.48
ψV/F 0.55 28.30
ψTa 0.16 35.76
ψAUC 0 -
σ (ng.mL−1) 732.29 8.40
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